flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

Notice of Business Alliance between Promethera Biosciences SA and MEDIPAL HOLDINGS

- Bringing Innovative Liver-Focused Cell Therapies to Japanese Markets -

Collaborations | 12 November 19
Read more
12
Nov
2019

Notice of Business Alliance between Promethera Biosciences SA and MEDIPAL HOLDINGS

- Bringing Innovative Liver-Focused Cell Therapies to Japanese Markets -

12
Nov
2019

Rocking (Roquin) the boat: Research on hemophagocytic syndrome uncovers new gene regulating the human immune system

Researchers from the VIB-UGent Center for Inflammation Research and the Ghent University hospital, together with research teams from the Helmholtz Zentrum in München and the National University of Australia in Canberra, identified a new genetic cause of hemophagocytic syndrome, a rare immune disease characterized by a dangerous and uncontrolled overproduction of cytokines known as cytokine storm. This discovery provides new insights into the human immune system and could inspire new treatments for this deadly immune disease.

11
Nov
2019

Promethera® Biosciences Presents Updated Clinical Results at AASLD 2019 for World’s First Stem Cell Therapy Trial using HepaStem™ in ACLF

3-Month Follow-up Data from the Fully Recruited Phase 2a Trial with a Total of 24 Patients Confirms Safety and Early Efficacy Trends and Dosing Regimen for Subsequent Trials

11
Nov
2019

MDxHealth Provides Q3-2019 Business Update

MDxHealth SA, a commercial-stage innovative molecular diagnostics company, today provided a business update for the three and nine months ended September 30, 2019.

9
Nov
2019

New data on Filgotinib in Rheumatoid Arthritis (RA) demonstrate durable efficacy and safety profile

-- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease Modifying Antirheumatic Drug(s) (csDMARDs) --
-- Data Demonstrate Efficacy and Safety Across a Wide Range of Patient Populations, Including Those Intolerant or Unresponsive to Biologic Treatment --
-- Data to be Presented at 2019 ACR/ARP Annual Meeting --

12
Nov
2019

Notice of Business Alliance between Promethera Biosciences SA and MEDIPAL HOLDINGS

- Bringing Innovative Liver-Focused Cell Therapies to Japanese Markets -

12
Nov
2019

Rocking (Roquin) the boat: Research on hemophagocytic syndrome uncovers new gene regulating the human immune system

Researchers from the VIB-UGent Center for Inflammation Research and the Ghent University hospital, together with research teams from the Helmholtz Zentrum in München and the National University of Australia in Canberra, identified a new genetic cause of hemophagocytic syndrome, a rare immune disease characterized by a dangerous and uncontrolled overproduction of cytokines known as cytokine storm. This discovery provides new insights into the human immune system and could inspire new treatments for this deadly immune disease.

11
Nov
2019

Promethera® Biosciences Presents Updated Clinical Results at AASLD 2019 for World’s First Stem Cell Therapy Trial using HepaStem™ in ACLF

3-Month Follow-up Data from the Fully Recruited Phase 2a Trial with a Total of 24 Patients Confirms Safety and Early Efficacy Trends and Dosing Regimen for Subsequent Trials

11
Nov
2019

MDxHealth Provides Q3-2019 Business Update

MDxHealth SA, a commercial-stage innovative molecular diagnostics company, today provided a business update for the three and nine months ended September 30, 2019.

9
Nov
2019

New data on Filgotinib in Rheumatoid Arthritis (RA) demonstrate durable efficacy and safety profile

-- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease Modifying Antirheumatic Drug(s) (csDMARDs) --
-- Data Demonstrate Efficacy and Safety Across a Wide Range of Patient Populations, Including Those Intolerant or Unresponsive to Biologic Treatment --
-- Data to be Presented at 2019 ACR/ARP Annual Meeting --

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?